Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma

Table 4 Analysis of serum TK1 activity (pmol/min/ml)^a

	Mean	Standard deviation	Median	Range
Controls (n = 40)	0.33	0.16	0.29	0.10–0.82
Confirmed lymphoma (n = 7)	4.7	6.1	2.5	0.28–17.7
Suspected lymphoma (n = 5)	3.3	2.2	3.2	0.18–6.5
Nontumour diseases (n = 107)	0.40	0.30	0.36	0.11–2.96

^aControls = horses without concurrent diseases (clinically healthy horses). Nontumour diseases = tumour-free horses with diverse concurrent diseases

ISSN: 2661-8850